Want to join the conversation?
$VRX stated that Xifaxan monthly TRx grew 28% year-over-year and it has seen an increase in the refill rate for the hepatic encephalopathy indication. The company has seen strong growth in other products in the GI franchise with three key products, Uceris, Relistor and Apriso, all growing in the mid to high single-digit range.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?